Cargando…

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies

Concurrent infections in hematological malignancies (HM) are major contributors to adverse clinical outcomes, including prolonged hospitalization and reduced life expectancy. Individuals diagnosed with HM are particularly susceptible to infectious pathogens due to immunosuppression, which can either...

Descripción completa

Detalles Bibliográficos
Autor principal:	Andreescu, Mihaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302360/ https://www.ncbi.nlm.nih.gov/pubmed/37374055 http://dx.doi.org/10.3390/life13061272

Ejemplares similares

Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy
por: Andreescu, Mihaela
Publicado: (2023)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia
por: Andreescu, Mihaela, et al.
Publicado: (2023)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
por: Fratta, Elisabetta, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies
por: Petty, Amy J., et al.
Publicado: (2019)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
por: Zhao, Ailin, et al.
Publicado: (2023)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

Targeting CD22 for B-cell hematologic malignancies
por: Xu, Jia, et al.
Publicado: (2023)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies
por: Sauter, Camille, et al.
Publicado: (2022)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy
por: Caivano, Antonella, et al.
Publicado: (2017)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease
por: Gondek, Lukasz P., et al.
Publicado: (2022)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
por: Mak, Joyce Wing Yan, et al.
Publicado: (2023)

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
por: Camus, Vincent, et al.
Publicado: (2017)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
por: Schütte, Judith, et al.
Publicado: (2019)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d11b8bdte76oee9bh96l153vob